Abbott Initiates Clinical Trial to Evaluate the Absorb™ Bioresorbable ... PR Newswire (press release) Abbott's BVS delivers everolimus, an anti-proliferative drug. Everolimus is developed by Novartis Pharma AG and is licensed to Abbott by Novartis for use on its drug eluting vascular devices. Everolimus has been shown to inhibit treated-site neointimal ... |
